BiotechTube
Invenio Imaging

Invenio Imaging

Santa Clara, United States· Est.
invenio-imaging.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $9.8M

Overview

Invenio Imaging is a private, commercial-stage company pioneering real-time intraoperative histology through its NIO Laser Imaging System, which leverages Stimulated Raman Histology (SRH) technology. The company has commercialized its core hardware system and has begun integrating artificial intelligence, evidenced by its CE-marked NIO Glioma Reveal algorithm for brain tumor surgery in the EU. Invenio targets multiple surgical subspecialties, including neurosurgery, pulmonology, and urology, with the goal of improving surgical decision-making and patient outcomes by providing rapid, on-site tissue analysis without destroying the sample.

Oncology

Technology Platform

Stimulated Raman Histology (SRH), a label-free coherent Raman scattering microscopy technique for rapid, non-destructive imaging of fresh tissue, generating digital histology-like images without staining or thin-sectioning.

Funding History

2
Total raised:$9.8M
Series A$8M
Seed$1.8M

Opportunities

The global shift towards digital pathology and AI-augmented diagnostics presents a massive growth opportunity.
Invenio's unique tissue-preserving capability allows it to tap into the personalized medicine market, where preserved samples are crucial for downstream genomic and biomarker testing.
Expansion into numerous surgical subspecialties (e.g., pulmonology, urology) provides multiple avenues for market penetration beyond its initial neurosurgery focus.

Risk Factors

Key risks include the challenge of changing entrenched surgical pathology workflows and securing hospital budgets for capital equipment.
Regulatory hurdles for full diagnostic claims of its AI algorithms, particularly FDA clearance in the U.S., pose significant timing and cost risks.
The company also faces potential competition from other emerging rapid intraoperative imaging technologies.

Competitive Landscape

Invenio competes in the intraoperative diagnostic imaging space against technologies like frozen section analysis, confocal microscopy (e.g., Caliber ID), optical coherence tomography, and mass spectrometry imaging. Its primary differentiation is the combination of speed (<3 minutes), high-resolution histology-like image quality, and non-destructive sample preservation. In the AI-powered digital pathology segment, it competes with software companies like Paige and PathAI, but with a unique focus on real-time, intraoperative data generation.

More companies in Diagnostics & Precision Medicine →More companies in United States →